

#10 125.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	09/834,760
Filing Date	April 12, 2001
First Named Inventor	Austin, Richard C.
Art Unit	1633
Examiner Name	Jon Angell
Attorney Docket Number	19874-000410

TECH CENTER 1600/2900

JUL 3 2002

RECEIVED

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
[Signature]	1	BREWER, et al., "A pathway distinct from the mammalian unfolded protein response regulates expression of endoplasmic reticulum chaperones in non-stressed cells," <i>EMBO J.</i> , 16(23):7207-7216 (1997)	
	2	CHAN, et al., "Effect of a novel covalent antithrombin-heparin complex on thrombin generation on fetal distal lung epithelium," <i>Lung Cell. Mol. Physiol.</i> , 18:L914-L921 (1998)	
	3	ELLIS, et al., "Molecular chaperones: proteins essential for the biogenesis of some macromolecular structures," <i>Trends Biochem. Sci.</i> , 14(8):339-42 (1989)	
	4	FLIEGEL, et al., "Molecular cloning of the high affinity calcium-binding protein (calreticulin) of skeletal muscle sarcoplasmic reticulum," <i>J. Biol. Chem.</i> , 264(36):21522-8 (1989)	
	5	KOZUTSUMI, et al., "Identification of immunoglobulin heavy chain binding protein as glucose-regulated protein 78 on the basis of amino acid sequence, immunological cross-reactivity, and functional activity," <i>J. Cell Sci. Suppl.</i> , 11:115-37 (1989)	
	6	LING, et al., "α ₂ -Macroglobulin remains as important as antithrombin III for thrombin regulation in cord plasma in the presence of endothelial cell surfaces," <i>Pediatr. Res.</i> , 37(3):373-378 (1995)	
	7	LIU, et al., "Endoplasmic reticulum chaperones GRP78 and calreticulin prevent oxidative stress, Ca ²⁺ disturbances, and cell death in renal epithelial cells," <i>J. Biol. Chem.</i> , 272(35):21751-21759 (1997)	
	8	LIU, et al., "Endoplasmic reticulum stress proteins block oxidant-induced Ca ²⁺ increases and cell death," <i>J. Biol. Chem.</i> , 273(21):12858-12862 (1998)	
	9	MICHALAK, et al., "Calreticulin," <i>Biochem. J.</i> , 285:681-92 (1992)	
	10	MORRIS, et al., "Immunoglobulin binding protein (BiP) function is required to protect cells from endoplasmic reticulum stress but is not required for the secretion of selective proteins," <i>J. Biol. Chem.</i> , 272(7):4327-34 (1997)	
	11	OUTINEN, et al., "Characterization of the stress-inducing effects of homocysteine," <i>Biochem. J.</i> , 332:213-221 (1998)	
	12	OUTINEN, et al., "Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells," <i>Blood</i> , 94(3):959-967 (1999)	
	13	OZAWA, et al., "Reticulocalbin, a novel endoplasmic reticulum Resident Ca ²⁺ -binding protein with multiple EF-hand motifs and a carboxyl-terminal HDEL sequence," <i>J. Biol. Chem.</i> , 268(2):699-705 (1993)	
	14	PENN, et al., "Hydrogen peroxide activates latent cell surface tissue factor," <i>Circulation</i> , 99:1753-1759 (1999)	
	15	RUDDON, et al., "Assisted protein folding," <i>J. Biol. Chem.</i> , 272(6):3125-3128 (1997)	
	16	SORGER, et al., "The glucose-regulated protein grp94 is related to heat shock protein hsp90," <i>J. Mol. Biol.</i> , 194:341-4 (1987)	

Examiner Signature


Date Considered

2.23.03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
WC 9042545 v1



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	09/834,760
Filing Date	April 12, 2001
First Named Inventor	Austin, Richard C.
Art Unit	1633
Examiner Name	Jon Angell
Attorney Docket Number	19874-000410

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	17	TING, et al., "Human gene encoding the 78,000-Dalton glucose-regulated protein and its pseudogene: structure, conservation, and regulation," DNA, 7(4):275-86 (1988)	
	18	WADA, et al., "SSR α and associated calnexin are major calcium binding proteins of the endoplasmic reticulum membrane," J. Biol. Chem., 266(29):19599-19610 (1991)	

RECEIVED

JUL 3 2002

TECH CENTER 1600/2900

Examiner
SignatureDate
Considered

2.23.03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
WC 9042545 v1